CN110678471B - Mk2抑制剂及其合成和中间体 - Google Patents

Mk2抑制剂及其合成和中间体 Download PDF

Info

Publication number
CN110678471B
CN110678471B CN201880032092.8A CN201880032092A CN110678471B CN 110678471 B CN110678471 B CN 110678471B CN 201880032092 A CN201880032092 A CN 201880032092A CN 110678471 B CN110678471 B CN 110678471B
Authority
CN
China
Prior art keywords
formula
compound
salt
base
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880032092.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110678471A (zh
Inventor
G·B·费格尔森
M·E·盖尔蒂
Jr·R·M·内斯
M·柯塔尔
H-W·曼
A·L·卢切尔曼
J·F·特拉弗斯
K·H-Y·勇
C·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Publication of CN110678471A publication Critical patent/CN110678471A/zh
Application granted granted Critical
Publication of CN110678471B publication Critical patent/CN110678471B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
CN201880032092.8A 2017-03-16 2018-03-15 Mk2抑制剂及其合成和中间体 Expired - Fee Related CN110678471B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472024P 2017-03-16 2017-03-16
US62/472,024 2017-03-16
PCT/US2018/022547 WO2018170203A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Publications (2)

Publication Number Publication Date
CN110678471A CN110678471A (zh) 2020-01-10
CN110678471B true CN110678471B (zh) 2022-09-13

Family

ID=63523971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880032092.8A Expired - Fee Related CN110678471B (zh) 2017-03-16 2018-03-15 Mk2抑制剂及其合成和中间体

Country Status (8)

Country Link
US (2) US10894796B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596086A4 (cg-RX-API-DMAC7.html)
JP (1) JP7282039B2 (cg-RX-API-DMAC7.html)
CN (1) CN110678471B (cg-RX-API-DMAC7.html)
AU (1) AU2018236290B2 (cg-RX-API-DMAC7.html)
CA (1) CA3054826A1 (cg-RX-API-DMAC7.html)
MX (1) MX387359B (cg-RX-API-DMAC7.html)
WO (1) WO2018170203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) * 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN116643046B (zh) * 2023-05-30 2025-09-12 南昌市高新区人民医院(南昌大学第一附属医院高新医院) Mk2在癌症恶病质肌肉萎缩中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189377A (zh) * 2010-10-29 2013-07-03 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
CN103269704A (zh) * 2010-11-01 2013-08-28 西建阿维拉米斯研究公司 杂环化合物和其用途
CN103391718A (zh) * 2010-12-06 2013-11-13 汇合生命科学股份有限公司 取代的吡啶酮-吡啶基化合物
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉（硫）酮类化合物及其用途
WO2016025561A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
BR112015000399A2 (pt) 2012-07-10 2017-06-27 Ares Trading Sa derivados de pirazolil pirimidina
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
EP3110874B1 (en) 2014-02-27 2018-03-21 Council of Scientific and Industrial Research Poly-benzimidazole with pyrene and anthracene flourophore
WO2017040449A1 (en) 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189377A (zh) * 2010-10-29 2013-07-03 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
CN103269704A (zh) * 2010-11-01 2013-08-28 西建阿维拉米斯研究公司 杂环化合物和其用途
CN103391718A (zh) * 2010-12-06 2013-11-13 汇合生命科学股份有限公司 取代的吡啶酮-吡啶基化合物
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉（硫）酮类化合物及其用途
WO2016025561A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The formation of 2-alkoxyquinolines from quinoline N-oxides in alcoholic media";Michael J. Dimsdale等，;《Journal of Heterocyclic Chemistry》;19790930;第16卷;第1209-1211页 *

Also Published As

Publication number Publication date
US20210139501A1 (en) 2021-05-13
US20200102326A1 (en) 2020-04-02
US10894796B2 (en) 2021-01-19
AU2018236290A1 (en) 2019-09-19
US11655257B2 (en) 2023-05-23
AU2018236290B2 (en) 2022-06-02
WO2018170203A1 (en) 2018-09-20
JP2020510063A (ja) 2020-04-02
CN110678471A (zh) 2020-01-10
EP3596086A4 (en) 2020-12-16
MX2019010642A (es) 2019-10-17
CA3054826A1 (en) 2018-09-20
JP7282039B2 (ja) 2023-05-26
MX387359B (es) 2025-03-18
EP3596086A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
CN110678471A (zh) Mk2抑制剂及其合成和中间体
ES2977683T3 (es) Derivados de bencimidazolona y análogos de los mismos, como moduladores de IL-17
CN113024544B (zh) 一种含氰基并杂环化合物及其用途
CN114072207A (zh) 双环化合物
ES2534096T3 (es) Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa
CN110869017B (zh) 细胞凋亡信号调节激酶1抑制剂及其使用方法
CA2992408A1 (en) Substituted aza compounds as irak-4 inhibitors
CA2958139A1 (en) Solid state forms of ibrutinib
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
CN104470913B (zh) 用于制造羟基化的环戊基嘧啶化合物的方法
AU2021304045B2 (en) Immunomodulator
WO2023141852A1 (zh) Cdk2抑制剂及其制备方法和用途
US6486163B1 (en) Thienopyranecarboxamide derivatives
US11220489B2 (en) Process for preparing indole carboxamide compounds
WO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
WO2018028491A1 (zh) 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
JP2022503943A (ja) Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
US6387909B1 (en) Thienopyranecarboxamide derivatives
CN115925684B (zh) 一种嘧啶类衍生物及其制备方法和应用
WO2010131738A1 (ja) アゼチジン化合物およびその医薬用途
TW202045515A (zh) 酯化合物
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
US20250042891A1 (en) Compound containing structure of a heteroaromatic ring, pharmaceutical composition thereof and application thereof
CN111747949A (zh) Bcl-2选择性抑制剂的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230619

Address after: new jersey

Patentee after: BRISTOL-MYERS SQUIBB Co.

Address before: Bermuda Hamilton

Patentee before: CELGENE AVILOMICS RESEARCH, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220913